An adaptive design for early clinical development including interim decision for single‐arm trial with external controls or randomized trial-Reference-Cited by-同舟云学术

An adaptive design for early clinical development including interim decision for single‐arm trial with external controls or randomized trial

Published:2022-01-21 Issue:3 Volume:21 Page:625-640
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Götte Heiko¹^ORCID,Kirchner Marietta²^ORCID,Krisam Johannes²,Allignol Arthur¹,Lamy Francois‐Xavier¹^ORCID,Schüler Armin¹^ORCID,Kieser Meinhard²^ORCID

Affiliation:

1. Global Biostatistics, Epidemiology & Medical Writing Merck Healthcare KGaA Darmstadt Germany

2. Institute of Medical Biometry University of Heidelberg Heidelberg Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2190

Reference43 articles.

1. ThomasDW BurnsJ AudetteJ CarrollA Dow‐HygelundC HayM.Clinical Development Success Rates 2006‐2015;2016.https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20%20BIO %20Biomedtracker %20Amplion%202016.pdf

2. Empowering phase II clinical trials to reduce phase III failures

3. Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review

4. Randomized Phase II Trials: Inevitable or Inadvisable?

5. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials;JCO Precision Oncology;2024-02

2. Propensity score‐incorporated adaptive design approaches when incorporating real‐world data;Pharmaceutical Statistics;2023-11-28

3. Estimation of treatment effects in early-phase randomized clinical trials involving external control data;Journal of Biopharmaceutical Statistics;2023-10-12

4. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials;Clinical Trials;2023-06-14

5. Innovative Hybrid Designs and Analytical Approaches Leveraging Real-World Data and Clinical Trial Data;Real-World Evidence in Medical Product Development;2023